The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | NAUTIKA1: safety and tolerability of neoadjuvant alectinib in ALK-positive NSCLC
Targeted therapies for patients with non-small cell lung cancer (NSCLC) are currently being explored in clinical trials in the adjuvant setting. However, the role of targeted treatments in the neoadjuvant setting for patients with resectable NSCLC remains unclear. Jay Lee, MD, The Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, shares preliminary results from the ALK-positive cohort in the Phase II NAUTIKA1 trial (NCT04302025) investigating the efficacy and safety of the ALK inhibitor alectinib as neoadjuvant treatment in patients with ALK-positive resectable NSCLC. The primary endpoint is major pathologic response and secondary endpoints include radiographic response, pathologic complete response, disease-free survival, event-free survival, overall survival, and safety. For this preliminary analysis, preliminary response, surgical outcomes, and safety data for the neoadjuvant period were assessed. Alectinib was found to be well tolerated in patients with ALK-positive NSCLC and considered feasible for neoadjuvant treatment. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
